Solitaire Mach. (522152)
CyclicalScore breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 1/1
Key Financials
| Current Price | ₹98.05 |
| Market Cap | ₹44.54 Cr |
| P/E Ratio | 32.87 |
| ROCE | 12.16% |
| ROE | 7.6% |
| Dividend Yield | 2.02% |
| Profit Growth | -53.52% |
| Debt/Equity | — |
| Sales Growth | -47.36% |
| 52-Week Range | ₹72.2 — ₹141 |
| Sector | Industrial Manufacturing |
| Book Value | ₹39.68 |
Strengths
- ROCE of 12.16% is higher than ROE, indicating some operational efficiency in capital employed.
- Dividend yield of 2.02% offers a cash return even during a profit slump.
- Book value of ₹39.68 per share provides a tangible asset base, though the stock trades at 2.47x book.
- Latest quarter still shows ₹4 Cr of sales, meaning the business is generating revenue, not idle.
Concerns
- Sales fell 47.36% and profits fell 53.52%, showing severe operational deterioration.
- Piotroski F-score of 3/9 signals weak financial health across profitability, leverage, and efficiency.
- Latest quarter net profit is ₹0 Cr, leaving no current earnings cushion.
- P/E of 32.87 and P/B of 2.47 are expensive for a business with declining sales and 7.6% ROE.
AI Analysis
At ₹98, Solitaire Mach presents a puzzling picture. The market is asking 32.87 times earnings, but those earnings have collapsed – sales down 47% and profits down 53%. My first rule is never pay for a business that is shrinking unless I see a clear path to recovery. Here, the latest quarter shows sales of just ₹4 crore and net profit of zero. There is no earnings power to justify the multiple. Return on equity is 7.6%, which is below what I would demand from a small industrial company. The Piotroski F-score of 3/9 is a red flag; it suggests deteriorating fundamentals across profitability, leverage, and efficiency. Book value is ₹39.68, yet the stock trades at ₹98, or 2.47 times book. For that premium, I need a durable moat and strong growth, not a 47% sales decline. The only bright spots are a 12.16% ROCE, which shows some operational efficiency, and a 2.02% dividend yield that rewards patient holders while waiting. But a dividend can be cut when profits vanish. Leverage is unknown – debt/equity is N/A – and promoter holding is not disclosed, so I cannot assess alignment or financial risk. This looks like a cyclical downturn in an industrial products business, but I have no evidence of an imminent upcycle. The 52-week range of ₹72 to ₹141 shows high volatility. I would rather wait for confirmation: a quarter with positive net profit, an improving F-score, and stabilising sales. Until then, this is a 'too hard' pile. Value means buying a rupee for 50 paise, not buying a shrinking business at 32 times earnings.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer